Vanguard Group Inc. Cuts Position in Haemonetics Corporation $HAE

Vanguard Group Inc. lessened its position in Haemonetics Corporation (NYSE:HAE - Free Report) by 1.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,099,621 shares of the medical instruments supplier's stock after selling 79,767 shares during the period. Vanguard Group Inc. owned about 10.15% of Haemonetics worth $324,081,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Voya Investment Management LLC grew its position in shares of Haemonetics by 820.5% in the 4th quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier's stock valued at $24,748,000 after purchasing an additional 282,521 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Haemonetics by 434.8% in the fourth quarter. The Manufacturers Life Insurance Company now owns 314,067 shares of the medical instruments supplier's stock valued at $24,522,000 after acquiring an additional 255,338 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Haemonetics in the fourth quarter worth $19,002,000. Fort Washington Investment Advisors Inc. OH increased its position in shares of Haemonetics by 88.6% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 517,086 shares of the medical instruments supplier's stock worth $32,861,000 after purchasing an additional 242,956 shares during the period. Finally, Schwartz Investment Counsel Inc. grew its position in Haemonetics by 148.0% in the first quarter. Schwartz Investment Counsel Inc. now owns 374,500 shares of the medical instruments supplier's stock valued at $23,799,000 after acquiring an additional 223,500 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

HAE has been the topic of a number of recent analyst reports. JMP Securities reaffirmed a "market outperform" rating and issued a $100.00 price objective on shares of Haemonetics in a research note on Tuesday, May 20th. Barrington Research decreased their price objective on Haemonetics from $95.00 to $86.00 and set an "outperform" rating for the company in a report on Friday, August 8th. Wall Street Zen downgraded Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Robert W. Baird initiated coverage on Haemonetics in a research report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price objective on the stock. Finally, Citigroup raised Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price target on the stock in a research report on Wednesday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $85.18.

Haemonetics Price Performance

Shares of HAE stock traded down $0.0850 during trading hours on Thursday, hitting $54.3650. The stock had a trading volume of 343,624 shares, compared to its average volume of 808,538. The stock's 50-day moving average price is $70.12 and its two-hundred day moving average price is $66.49. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04. Haemonetics Corporation has a one year low of $50.68 and a one year high of $94.99. The stock has a market capitalization of $2.62 billion, a price-to-earnings ratio of 16.63, a PEG ratio of 1.00 and a beta of 0.40.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, beating analysts' consensus estimates of $1.01 by $0.09. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The firm had revenue of $321.39 million for the quarter, compared to analysts' expectations of $305.12 million. During the same quarter in the prior year, the firm posted $1.02 earnings per share. The company's quarterly revenue was down 4.4% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. Equities analysts forecast that Haemonetics Corporation will post 4.55 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.